Syndax制药 SNDX 深 沪
已收盘 11-07 16:00:00 美东时间
15.04
+0.350
+2.38%
华盛通- 最 高15.06
- 今 开14.57
- 成交量 216.28万股
- 最 低 13.8801
- 昨 收 14.69
- 总市值 12.96亿
- 52周最高 17.50
- 市盈率 静 --
- 换手率 2.51%
- 52周最低 8.58
- 委 比 -38.90%
- 总股本 8614.19万
- 历史最高 29.86
- 量 比 0.53
- 振 幅 8.03%
- 历史最低 3.39
- 每 手 1
- 风险率 2.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22
Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $19 to $22.
11-04 22:03
Syndax Pharmaceuticals Q3 EPS $(0.70) Beats $(0.73) Estimate, Sales $45.871M Miss $47.976M Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.73) by 3.98 percent. This is a 28.57 percent increase over losses of $(0.98) per share
11-04 05:03
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported $45.9 million in third-quarter revenue, up 21% from Q2, driven by strong demand for Revuforj and Niktimvo. Revuforj net revenue rose 12% to $32.0 million, with prescriptions up 25% to 850. Niktimvo net revenue was $45.8 million, yielding $13.9 million in collaboration revenue for Syndax. The FDA approved Revuforj for R/R NPM1m AML on October 24, marking it as the first and only approved therapy for both R/R AML and...
11-03 21:01
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
<p>Syndax Pharmaceuticals announced the acceptance of 23 abstracts, including six oral presentations, showcasing data for Revuforj<sup>®</sup> (revumenib) and Niktimvo™ (axatilimab-csfr) at the 67th ASH Annual Meeting in December 2025. These abstracts highlight promising results for revumenib in acute leukemia and axatilimab in chronic GVHD, with a focus on tolerability, long-term benefits, and combination therapies. The company also plans to hos...
11-03 14:08
Syndax Pharmaceuticals's Earnings Outlook
Syndax Pharmaceuticals (NASDAQ:SNDX) will release its quarterly earnings report...
11-01 04:02
Syndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and管理团队will participate in several investor conferences in November 2025, including the UBS Global Healthcare Conference, Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference. Details on the fireside chats are provided, and webcasts will be available on the company's website. Syndax, a biopharmaceutical company focused on ...
10-30 11:00
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target
BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.
10-27 17:25
